In this MasterClass, Dr. Justin Schweitzer discusses the applications of pharmaceutical presbyopia treatment options and ideal patients for treatment. By the end of this course, you will understand the differences between the pharmaceutical options and learn strategies to incorporate them into your practice.
This independent educational activity is supported by unrestricted educational grants from Johnson & Johnson Vision and Visus Therapeutics.
Upon completion of this activity, the participant should be able to:
Sponsored by 
Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.
This activity, COPE Activity Number 124263, is accredited by COPE for continuing education for optometrists for 0.25 hours.
Course #: 78857-GO
Activity #: 124263
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Justin Schweitzer, OD, FAAO
Vance Thompson Vision
Sioux Falls, SD
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Justin Schweitzer, OD, FAAO, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Aerie, Alcon, Allergan, Bausch + Lomb, Ocular Therapeutix, EyePoint Pharma, Sight Sciences, Dompé, Carl Zeiss Meditec, Visus, Science Based Health, Kala, Sun, Reichert, Johnson & Johnson, Glaukos, Horizon, Quidel, MediPrint, LKC, Avellino, and Novartis. Speaker's Bureau: Aerie, Alcon, Allergan, Bausch + Lomb, Sight Sciences, Carl Zeiss Meditec, Sun, Glaukos, and LKC. Investor: Equinox.
The Evolve and The Fundingsland Group staff, planners, and reviewers have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Johnson & Johnson Vision, or Visus Therapeutics.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Eric D. Donnenfeld, MD
Marjan Farid, MD
Jason J. Jones, MD
Eva I. Liang, MD, FACS
Carlton Yuen, MD
